TNF and adult-onset Still disease: While a randomized controlled trial has not yet assessed the safety and effectiveness of TCZ for AOSD, a number of case and pilot studies have demonstrated that TCZ treatment improved the clinical symptoms and signs of AOSD in patients who had not responded to standard treatment plans or biologics, such as anakinra and TNF inhibitors.